BackNovozymes A/S Overview

Novozymes A/S Total Liabilities

Track Novozymes A/S's total liabilities ($5.6B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$5.61B
↑ 0.62% YoYΔ $34.70M vs prior year quarter

Peer trimmed avg / median

Loading

Novozymes A/S Total Liabilities History

Loading

Novozymes A/S vs. peers: Total Liabilities Comparison

Loading

Novozymes A/S Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Novozymes A/S (NVZMF) FAQ

The latest total liabilities for NVZMF is $5.6B as of September 2026. That compares with $5.6B in the prior-year period — up 0.6% year over year. Investors often review this figure alongside Novozymes A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVZMF's total liabilities moved from $5.6B to $5.6B — a 0.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novozymes A/S's operating scale or balance-sheet position.

A total liabilities figure of $5.6B for NVZMF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NVZMF's total liabilities ($5.6B), review year-over-year change from $5.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.